

For personal use only



ALEXIUM
SPECIALTY CHEMICALS AND SOLUTIONS

INNOVATION. GROWTH. LEADERSHIP




FY 2017
PRELIMINARY FINAL REPORT

AUGUST 31 | 2017

For personal use only



FY2017 Achievements



In FY2016, the focus of the company was sales and revenue generation. FY2017 shifted the focus to bottom-line profitability while continuing the growth from the previous fiscal year. Alexium's success in achieving those goals further validates not just that Alexium's products are effective, but have a high level of value in the marketplace. In addition, Alexium's expansion into a second major product line diversified the Company's customer base and revenue profile.

REVENUE

Revenue from all ordinary activities was \$24 million, up 595% over FY2016. Top-line growth during the second year of true commercial sales further solidifies Alexium's strong position in the specialty chemical supply market.

MARGINS

Following initial lower margin business in FY2016 used to establish demonstrable supply chain reliability and initial market penetration, FY2017 gross margins on chemical sales improved from -12.08% to 1.24 %. Reaching economies of scale with supply chain partners and rapid growth in 2H2017 from our Alexicool™ product line provided the foundation for realizing positive margins, culminating with June 2017 monthly margins of 30.6%. This positive trend has continued through the reporting date closer to a margin goal of greater than 40%.



FY2017 Achievements (contd.)

CASH POSITION


At the end of the period, the Company had \$3.4M in cash and \$1.4M in receivables. In addition to cash on hand, the Company will be imminently closing a US\$10 million debt facility which together with cash generation from higher realized margins provides a solid foundation to Alexium's position to finance working capital for growth. The Company is expecting closing on the new debt facility on Friday September 1st. Alexium does not need to raise additional equity and will only do so to finance rapid growth arising from large defense sector sales or other areas where large orders require additional working capital.

CASH NEUTRALITY

June sales of \$2.1M and 30+ percent margins allowed Alexium to achieve cash neutrality for the month, a key milestone for the Company. This sales and margin trend has continued through the reporting date.

PRODUCT EXPANSION

The company developed six new targeted platform products in FY2017 to address large unmet market needs in bedding, cellulotics (cotton, fleece, wood), pillow shells, work wear, underwear/active wear and tenting.





FY2017 Results Overview

SIGNIFICANT NEW BUSINESS WITH NEW ALEXICOOL™ PRODUCT

Alexium launched a new phase change material (PCM) chemistry. A blended product, containing Alexicool™, Alexiflam™ FR, anti-odor agents, binders and dye transfer resistant agents had a strong reception in the bedding market, largely in 2H2017.

TECHNICAL ADVANCEMENT AND PROGRESS TO MARKET FOR ALEXIFLAM™ NF

Alexium modified its initial Alexiflam™ NF product, following initial license negotiations in 2016, to successfully pass the strictest global durability standards for FR cotton - 100 industrial launderings for European workwear. This additional effort was a means of capturing higher value product opportunities with potential licensees. This strong FR performance of this product has attracted multiple interested parties for development, manufacturing and exclusivity licensing arrangements in the US and Europe. License negotiations have recommenced upon achieving the industrial laundering standard.

Further, we have gained a greater understanding of the different market dynamics between the US and Europe for natural fiber FR and are factoring those differences into our license planning.

DEVELOPMENT OF THREE NEW ADDITIONAL PRODUCTS IN ALEXICOOL™ LINE

In addition to the initial Alexicool™ product for mattress components, the Company developed three additional market-specific variants – semi-durable back coating for pillows, an “invisible” pad treatment for non-white fabrics (work wear), and a wash-durable combination of PCM and moisture-wicking chemistry.

PROGRESS IN MILITARY WITH NEW FABRIC PARTNER

Alexium partnered with a major defense sector contractor and producer of nylon-cotton fabrics to tailor the weight and breathability of the base military fabric to which Alexium’s proven FR components can be added with the goal of securing a major military uniform program. Alexiflam™ FR has met the US Department of Defense standards and work with the Army and Marines has been to address lighter weight fabrics for the best product combination to meet the US DoD’s objective.



FY2017 Results Overview

ADMINISTRATIVE COSTS

Administrative costs increased this year by \$0.15M, but dropped from 40% to 6% of total revenue. In October, 2016, Alexium finalized the build of its new, state of the art facility. Alexium was able to realize several operational benefits from the new facility including a reduction in administrative costs by US\$0.15M to be realized over the first 5 years of the lease. Continued reductions in administrative costs in relation to revenue are planned for FY2018.

EMPLOYEE BENEFITS EXPENSE

Employee costs increased by \$1.4M but decreased as a percent of total revenue to 21% from 108% in FY2016. This trend is expected to continue and the Company is expecting a reduction in staffing costs in FY2018 as post year-end reductions have occurred. Board costs and Executive Director costs have been substantially reduced following a combination of the Board voting to lower Board and Committee Fees for FY18, the retirement of the Executive Director of Strategy and the move of the Executive Chairman to Non-Executive Chairman.

PROFESSIONAL FEES

The Company realized a \$0.6M reduction in professional service fees for the period due to consolidation of external service providers. This trend is expected to continue as Alexium continues to grow.

OTHER EXPENSES

An overall reduction in other expenses of \$0.5M was largely due to the Company's continued diligence monitoring extraneous expenses and cutting unnecessary costs.

SHARE-BASED PAYMENTS


There was a significant reduction in share issuance costs in FY2017. This is a result of greatly reduced option issuance and share based payment in lieu of services provided to external consultants. This trend is expected to continue.

FINANCE COSTS


An increase in finance costs from Nil to \$0.6M was a result of the Company's debt facility which was funded in December of 2016. The interest rate for this debt is expected to decrease in 2018 as a result of the company refinancing under improved terms. The debt facility refinance will also add additional capital, so finance costs are expected to increase in FY2018 but decrease as a percent of total outstanding debt. In addition to the reductions in costs in other areas noted above, and the Company's margin and revenue improvements equating to more free cash flow, this refinance will allow Alexium to completely fund its growth moving forward.



FY2017 Growth Trends




- Revenue from chemistry sales up 693% from \$3M to \$24M
- Margin on chemical sales grew by 13.3 percentage points




- Sales Revenue grew 12% in the second half of the year as a result of continued gains in the mattress industry
- Gross Margin gain of 4.2 percentage points from 1H to 2H was due to supply chain improvements and production scale pricing with raw material suppliers with this trend continuing



FY2017 Results Overview (cont.)- Growth Trends



- Revenue Increased by 15% in Q4 due to bedding sales ramping to record highs
- Gross Margins increased by 32.3 percentage points as ramp up in bedding sales allowed for better raw materials pricing in Q4 from economies of scale



- Revenue in Q4 showed continued growth over previous periods
- June revenues slightly lower than previous months due to US Independence Day holiday slowing production for end customers
- Margins showed steady progression towards our calendar end of year target of 40%
- 31% margins on June sales directly contributed to Alexium reach a cash neutral position on pace to meet its mid-year goal



FY2017 Growth in Revenue


SHIFT IN BUSINESS STRATEGY

Due to the FY2016 strategy of developing reliable supply chains and achieving market penetration and awareness, top-line revenue accelerated in FY2016 and 1H2017 while margins lagged. This largely bespoke business strategy resulted in a large number of low-volume raw materials resulting in high product COGS and negative margins. In FY2017, having created market awareness of our products, the Company successfully shifted its strategic focus to larger markets with unmet technological needs or price points for which single products could be disruptive and economies of scale rapidly achieved.

Additionally, the Company strategically reduced the number of low volume raw materials to reduce average customer COGS and raised prices to eliminate long-term low (or negative) margin revenue streams.

RAPID GROWTH OF ALEXICOOL™ IN THE BEDDING INDUSTRY

Based on the strength of the value proposition of the Company's Alexicool™ product introduced to the mattress industry, supply of Alexium chemistry into that industry increased from non-existent to over 90 metric tons per month by the end of FY2017.





FY2018 Results to Date

- Secured new mattress Alexicool™ ticking business through two new fabric finishers, including one of the largest consumers of PCM in the world
- Developed key strategic partner to validate and commercialize Alexiflam™ NF for mattress sock application
- Working with one of the world's largest apparel manufactures with durable PCM apparel applications
- Currently testing fabric for AlexiFlam™ NF work wear applications with key manufactures in India and Pakistan
- Launched new all-in-one Alexiflam™ FR product for tenting fabrics at the 2017 Outdoor Retailer show
- A US\$10M debt facility with targeted final closing on September 1st 2017 will place the company in a well capitalized position to facilitate future growth targets.
- Recent testing of Alexium-treated military uniforms reinforce 25 wash durability of Alexiflam FR treatments. The Company will work closely with fabric partners to fine tune initial fabric weight to meet Department of Defense requirements.



Outlook



MILITARY

The Company will continue to work with strategic fabric and garment partners to advance its progress towards achieving major military contracts in FY2018. Work will focus on breathability and weight of the base fabric as durability of the flame retardant treatments continue to meet performance requirements. In addition, the Company will begin to identify potential licensees of its proprietary Reactive Surface Treatment technology as global chemical and biological threats are increasing.

FORM STRATEGIC PARTNERSHIPS FOR GLOBAL ALEXIFLAM™ NF LAUNCH

Due to significant industry interest in the value proposition of Alexiflam™ NF, Alexium will be forming strategic partnerships to maximize the value of Alexiflam™ NF for its shareholders. Those partnerships will likely include exclusive licensees for various markets and manufacturing agreements.

IMPROVEMENT IN FINANCIALS AND PROFITABLE GROWTH

Through a combination of price increases and supply chain management, Alexium will continue to convert its earlier market penetration revenue streams to profitability. In addition, increasing market share in current markets and expansion into new markets will result in profitable growth.

EXPANSION OUTSIDE OF TEXTILES

Efforts began in FY2017 to diversify Alexium's revenue streams outside of textiles. Several of these opportunities are expected to materialize in FY2018. While a continued push into epoxy/polymeric markets is ongoing, the Company also has market adoptions planned in protective coatings and wood treatments.

CONTINUED GROWTH IN BEDDING AND PILLOWS

Planned expansion into the pillow market with Pegasus Home Fashions will continue to drive revenues upward and the number of bedding brands using Alexium chemistry will increase. Through the reporting date Alexium has already added two new bedding customers.

COMMERCIALIZATION OF TENTING TREATMENT

Alexium's all-in-one Oeko-tex Certified tent fabric treatment (including FR, water repellency, coatings and binders) to realize penetration into highly eco-conscious tenting market space.

Appendix 4E

Preliminary final report

Name of entity:

Alexium International Group Limited

ABN or equivalent company
reference:

91 064 820 408

1. Reporting period

Reporting period:

Year ended 30 June 2017

Previous corresponding period:

Year ended 30 June 2016

2. Results for announcement to the market

\$A

2.1 Revenue from ordinary activities	up	595%	to	24,034,416
2.2 Loss from ordinary activities for the period after tax attributable to members	down	21%	to	(12,155,268)
2.3 Net loss for the period attributable to members	down	21%	to	(12,155,268)
2.4 Dividends		Amount per security		Franked amount per security
Final dividend		Nil		N/A
Interim dividend		Nil		N/A
2.5 Record date for determining entitlements to the dividends		N/A		

For personal use only

2.6 Brief explanation of any of the figures reported above to enable the figures to be understood:

The reporting period ended 30 June 2017 saw significant growth in revenue from ordinary activities with increases in demand for our primary product lines, Alexiflam FR and Alexicool. This represents a 595% increase in sales (732% in 2015) over the previous period. Loss from ordinary activities was down 21% over the previous year because of several areas of improvement, with the largest advances occurring with more favourable pricing terms from supplier and manufacturing partners based on the sizeable volume increases and cost management efforts undertaken by the finance team. The addition of debt funding during the period provided valuable working capital to fuel growth, which far outweighs the increases to finance and derivative liability costs incurred. Significant capital assets were added to the balance sheet during the period by means of purchase and capital lease. Additions included a purpose-built facility to house all US operations, lab equipment to further product development efforts, and office equipment for added staff. Increased depreciation expenses are directly related to this facility and equipment, which has become a key driver in promoting cross functional collaboration of internal and external partners, in turn increasing the productivity, progress and profits.

For personal use only

3. Consolidated Statement of Comprehensive Income

	Current Period 2017 \$	Previous Period 2016 \$
Revenues from continuing operations	24,034,416	3,457,932
Cost of goods sold	(23,516,103)	(3,363,839)
Administrative expenses	(1,512,740)	(1,361,276)
Employee benefits expense	(5,104,877)	(3,672,088)
Depreciation and amortisation expenses	(359,241)	(204,473)
Research and development	(1,878,367)	(1,984,423)
Professional fees	(1,525,349)	(2,130,604)
Other expenses	(1,507,547)	(2,010,910)
Share based payments	-	(4,175,190)
Change in fair value of derivative liability	(189,276)	-
Finance costs	(596,184)	-
Operating loss	(12,155,268)	(15,444,871)
Loss before income tax	(12,155,268)	(15,444,871)
Income tax (expense) / benefit	-	-
Loss after income tax expense from continuing operations	(12,155,268)	(15,444,871)
Attributable to:		
Members of the Parent Company	(12,155,268)	(15,444,871)
Items that may be reclassified to profit or loss		
Net exchange difference on translation of financial report of foreign controlled entity	(78,350)	459,291
Total other comprehensive income	(78,350)	459,291
Total comprehensive loss for the year	(12,233,618)	(14,985,580)
Basic loss per share (cents per share)	(4.03)	(6.97)
Diluted loss per share (cents per share)	(4.03)	(6.97)

4. Consolidated Statement of Financial Position

	Detailed Financial Note	Current Period 30 June 2017 \$	Previous Period 30 June 2016 \$
Current Assets			
Cash and cash equivalents		3,409,783	11,218,556
Trade and other receivables	11	1,427,908	191,762
Inventories		2,091,028	1,656,669
Other current assets		101,129	90,869
Total Current Assets		7,029,848	13,157,856
Non-Current Assets			
Other financial assets		35,530	37,094
Property, plant and equipment	11	2,441,920	816,738
Intangible assets		143,299	148,454
Total Non-Current Assets		2,620,749	1,002,286
Total Assets		9,650,597	14,160,142
Current Liabilities			
Trade and other payables		1,830,037	2,817,172
Deferred income		32,458	18,365
Borrowings	11	5,854,376	38,526
Other liabilities		263,772	-
Total Current Liabilities		7,980,643	2,874,063
Non-Current Liabilities			
Borrowings		394,077	18,549
Derivative liability		1,056,403	-
Total Non-Current Liabilities		1,450,480	18,549
Total Liabilities		9,431,123	2,892,612
Net Assets		219,474	11,267,530
Equity			
Issued capital		52,820,041	51,634,479
Reserves		8,973,213	9,051,563
Accumulated losses		(61,573,780)	(49,418,512)
Total Equity		219,474	11,267,530

5. Consolidated Statement of Cash Flows

	Current Period 30 June 2017 \$	Previous Period 30 June 2016 \$
Cash flows from operating activities		
Receipts from customers	22,433,226	3,318,758
Payments to suppliers and employees	(34,774,370)	(13,515,181)
Interest received	12,018	44,018
Interest and other costs of finance paid	(512,582)	-
Goods & services tax (paid) / received from ATO	114,186	76,044
Net cash used in operating activities	(12,727,522)	(10,076,361)
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,597,678)	(181,484)
Investments in and maintenance of intangible assets	-	(28,276)
Other non-current assets	(21,529)	-
Proceeds from disposal of property, plant and equipment	547	-
Net cash flows from investing activities	(1,618,660)	(209,760)
Cash flows from financing activities		
Proceeds from issue of ordinary shares	-	6,000,000
Proceeds from exercise of options	663,033	3,906,113
Proceeds from borrowings	6,674,676	-
Payment of share issue costs	-	(396,000)
Transaction costs related to loans and borrowings	(126,085)	-
Payment of financing lease principal	(167,862)	-
Net cash flows from financing activities	7,043,762	9,510,113
Net increase / (decrease) in cash held	(7,302,420)	(776,008)
Cash and cash equivalents at the beginning of the period	11,218,556	11,621,603
Effects of exchange rate changes on cash	(506,353)	372,961
Cash and cash equivalents at the end of the period	3,409,783	11,218,556

6. Consolidated Statement of Changes in Equity

	Contributed equity \$	Reserves \$	Accumulated losses \$	Total \$
Balance at 1 July 2016	51,634,479	9,051,563	(49,418,512)	11,267,530
Loss for the year	-	-	(12,155,268)	(12,155,268)
Foreign currency translation	-	(78,350)	-	(78,350)
Total comprehensive loss for the year	-	-	(12,155,268)	(12,233,618)
Transactions with owners in their capacity as owners:				
Options exercised	663,033	-	-	663,033
Shares issued in lieu of salary	522,529	-	-	522,529
Balance at 30 June 2017	52,820,041	8,973,213	(61,573,780)	219,474

	Contributed equity \$	Reserves \$	Accumulated losses \$	Total \$
Balance at 1 July 2015	41,363,396	4,417,082	(33,973,641)	11,806,837
Loss for the year	-	-	(15,444,871)	(15,444,871)
Foreign currency translation	-	459,291	-	459,291
Total comprehensive loss for the year	-	459,291	(15,444,871)	(14,985,580)
Transactions with owners in their capacity as owners:				
Issued capital	6,000,000	-	-	6,000,000
Capital raising costs	(369,000)	-	-	(369,000)
Options exercised	3,906,113	-	-	3,906,113
Share-based payment	454,690	4,175,190	-	4,629,880
Shares issued in lieu of salary	279,280	-	-	279,280
Balance at 30 June 2016	51,634,479	9,051,563	(49,418,512)	11,267,530

7. Dividends (in the case of a trust, distributions)

Date dividend is payable	N/A
Record date to determine entitlements to the dividend	N/A
If it is a final dividend, has it been declared?	N/A

Amount per security

	Amount per security	Franked amount per security at 30% tax (see note 4)	Amount per security of foreign source dividend
Final dividend: Current year	Nil	N/A	N/A
Interim dividend: Current year	Nil	N/A	N/A

Total dividend (distribution) per security (interim plus final)

	Current period	Previous Period
Ordinary securities	N/A	N/A
Preference securities	N/A	N/A

8. Dividend or distribution plans in operation

N/A

The last date(s) for receipt of election notices for the dividend or distribution plans	N/A
---	-----

9. Consolidated retained profits/accumulated losses

	Current Period 2017 \$	Previous Period 2016 \$
Accumulated losses at the beginning of the financial period	(49,418,512)	(33,973,641)
Net loss attributable to members	(12,155,268)	(15,444,871)
Accumulated losses at end of financial period	(61,573,780)	(49,418,512)

10. NTA backing

	Current Period 2017	Previous Period 2016
Net tangible asset backing (deficiency) per ordinary share	0.02 cents	3.72 cents

11. Significant information

Trade and other receivables

	2017	2016
Trade debtors	1,365,116	136,544
Other receivables	<u>62,792</u>	<u>55,218</u>
	<u>1,427,908</u>	<u>191,762</u>

Property, Plant and Equipment

	Furniture & Equipment	Leased assets	Construction In Progress	Total
Cost or valuation	\$	\$	\$	\$
Balance at 30 June 2015	728,879	436,046	-	1,164,925
Additions	161,493	-	322,838	484,331
Disposals	(18,838)	-	-	(18,838)
Foreign exchange movements	1,462	12,687	607	14,756
Balance at 30 June 2016	<u>872,996</u>	<u>448,733</u>	<u>323,445</u>	<u>1,645,174</u>
Additions	1,661,294	701,809	1,115,778	3,478,881
Disposals	(107,614)	-	(1,428,914)	(1,536,528)
Foreign exchange movements	(67,175)	(30,361)	(10,309)	(107,845)
Balance at 30 June 2017	<u>2,359,501</u>	<u>1,120,181</u>	<u>-</u>	<u>3,479,682</u>
Depreciation and impairment				
Balance at 30 June 2015	362,513	287,793	-	650,306
Depreciation	134,566	54,445	-	189,011
Disposals	(18,838)	-	-	(18,838)
Foreign exchange movements	752	7,205	-	7,957
Balance at 30 June 2016	<u>478,993</u>	<u>349,443</u>	<u>-</u>	<u>828,436</u>
Depreciation	236,294	106,644	-	342,938
Disposals	(102,311)	-	-	(102,311)
Foreign exchange movements	(18,071)	(13,230)	-	(31,301)
Balance at 30 June 2017	<u>594,905</u>	<u>442,857</u>	<u>-</u>	<u>1,037,762</u>
Net book value				
At 30 June 2015	366,366	148,253	-	514,619
At 30 June 2016	<u>394,003</u>	<u>99,290</u>	<u>323,445</u>	<u>816,738</u>
At 30 June 2017	<u>1,764,596</u>	<u>677,324</u>	<u>-</u>	<u>2,441,920</u>

Current liabilities - Borrowings

	2017	2016
Credit Facility	5,665,227	-
Current capital leases payable	<u>189,149</u>	<u>38,526</u>
	<u>5,834,376</u>	<u>38,526</u>

12. Foreign entities set of accounting standards used in compiling the report (IAS)

IFRS

13. Commentary on the results for the period

13.1 Earnings per security (EPS)

	Current Period 2017	Previous Period 2016
Basic Loss per share (cents)	(4.03 cents)	(6.97 cents)

13.2 Returns to shareholders (Including distributions and buy backs)

	Current Period 2017 \$	Previous Period 2016 \$
Ordinary securities	-	-
Preference securities	-	-
Other equity instruments	-	-
Total	-	-

The dividend or distribution plans shown below are in operation.

N/A

The last date(s) for receipt of election notices for the dividend or distribution plans

N/A

Any other disclosures in relation to dividends (distributions).

N/A

For personal use only

13.3 Significant features of operating performance

The period ended 30 June 2017 had many significant features and achievements, but the most notable was the significant growth of revenue and further expansion into target markets and regions. The strong demand for Alexium's proprietary chemistry applications to bedding products led the surge of new customers and large scale recurring orders. Across the industry, bedding manufacturers are now viewing phase change applications to be essential features of their offerings and Alexicool is poised to be a market leading solution. The outdoor industry too is undergoing a shift in consumer demand based on multiple reports detailing the harmful nature of common flame retardant applications. Our efforts with tenting manufacturers have generated sizeable recurring orders and the development of new custom solutions to customer demands.

13.4 Segment Information

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group's other components. The Company has applied IFRS 8 Operating Segments which requires a 'management approach' under which segment information is presented on the same basis as that used for internal reporting purposes.

For management purposes, the Group is organised into one main operating segment which involves the development and licensing of its proprietary flame retardant (FR) and phase change material (PCM) chemistries, reactive surface treatment (RST) technologies, and selling its specialized chemistry to customers. All of the Group's activities are interrelated and discrete financial information is reported to the Chief Executive Officer (Chief Operating Decision Maker) as a single segment. Accordingly, all significant operating decisions are based upon analysis of the Group as one segment.

13.5 Report on trends in performance

The most notable trend of the reporting period is the improvement of gross margins on core products. Overall margin for the period was dragged down by low-margin but high-volume orders from the early months of the period. However, a combination of improved supply pricing terms, increased manufacturing efficiency and a more selective approach to development have increased the gross margin on core products to over 40%.

13.6 Report any factors which have affected the results during the reporting period or which are likely to affect results in the future, including those where the effect could not be quantified.

Refer to the cover letter from the CEO

Any other information required to be disclosed to enable the reader to compare the information presented with equivalent information for previous periods. This must include information needed by an investor to make an informed assessment of the entity's activities and results.

N/A

14. Compliance statement

This report is based on accounts to which one of the following applies.
(Tick one)

- | | | | |
|-------------------------------------|--|--------------------------|---|
| <input type="checkbox"/> | The accounts have been audited. | <input type="checkbox"/> | The accounts have been subject to review. |
| <input checked="" type="checkbox"/> | The accounts are in the process of being audited or subject to review. | <input type="checkbox"/> | The accounts have not yet been audited or reviewed. |

15. If the accounts have not yet been audited or subject to audit review and are likely to be subject to dispute or qualification, a description of the likely dispute or qualification:

This report is based upon accounts which are in the process of being audited, but the company does not anticipate any dispute or qualification.

16. If the accounts have been audited or subject to review and are subject to dispute or qualification, a description of the dispute or qualification:

This report is based upon accounts which are in the process of being audited, but the company does not anticipate any dispute or qualification.



Sign here: Date: 31 August 2017
(Chief Executive Officer)

Print name: Dirk Van Hyning

For personal use only